|
gptkbp:instanceOf
|
antipsychotic medication
|
|
gptkbp:approvalYear
|
2010
|
|
gptkbp:approvedBy
|
gptkb:United_States
|
|
gptkbp:ATCCode
|
N05AE05
|
|
gptkbp:availableOn
|
gptkb:Australia
gptkb:Canada
gptkb:Europe
gptkb:Japan
gptkb:United_States
|
|
gptkbp:brand
|
gptkb:Latuda
|
|
gptkbp:CASNumber
|
367514-87-2
|
|
gptkbp:chemicalClass
|
benzisothiazol derivative
|
|
gptkbp:compatibleWith
|
dementia-related psychosis
|
|
gptkbp:contraindication
|
strong CYP3A4 inducers
strong CYP3A4 inhibitors
|
|
gptkbp:developedBy
|
gptkb:Dainippon_Sumitomo_Pharma
|
|
gptkbp:eliminationHalfLife
|
18 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:foodInteraction
|
should be taken with food
|
|
gptkbp:form
|
gptkb:tablet
|
|
gptkbp:hasMolecularFormula
|
C28H36N4O2S
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Lurasidone
|
|
gptkbp:KEGGID
|
D08167
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
dopamine D2 receptor antagonist
serotonin 5-HT2A receptor antagonist
partial agonist at 5-HT1A receptor
serotonin 5-HT7 receptor antagonist
|
|
gptkbp:metabolism
|
liver (CYP3A4)
|
|
gptkbp:pregnancyCategory
|
C (US)
B3 (Australia)
|
|
gptkbp:prescribes
|
adults with schizophrenia
adolescents with schizophrenia
adults with bipolar depression
|
|
gptkbp:proteinBinding
|
99.8%
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL2105757
213046
DB08815
184070
|
|
gptkbp:riskFactor
|
increased mortality in elderly with dementia-related psychosis
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
weight gain
somnolence
parkinsonism
akathisia
|
|
gptkbp:synonym
|
SM-13496
|
|
gptkbp:UNII
|
7I6U6WLE1U
|
|
gptkbp:usedFor
|
schizophrenia
bipolar depression
|
|
gptkbp:bfsParent
|
gptkb:D08513
|
|
gptkbp:bfsLayer
|
7
|